MoonLake Immunotherapeutics (MLTX) News Today → Read this before you buy AI stocks (From InvestorPlace) (Ad) Free MLTX Stock Alerts $38.66 -1.09 (-2.74%) (As of 05/20/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 5:04 AM | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Reaffirmed by HC WainwrightMay 17 at 12:54 PM | markets.businessinsider.comBuy Rating Reaffirmed for MoonLake Immunotherapeutics Amidst Promising Clinical Trials and Strategic Development PlansMay 17 at 11:15 AM | marketbeat.comMoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research note on Friday.May 16, 2024 | globenewswire.comMoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaMay 14, 2024 | marketbeat.comVictory Capital Management Inc. Has $9.34 Million Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)Victory Capital Management Inc. trimmed its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 15.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,607 sharMay 13, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for MoonLake Immunotherapeutics Lifted by Analyst (NASDAQ:MLTX)May 12, 2024 | seekingalpha.comMoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market ExpansionMay 12, 2024 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Earns "Buy" Rating from Needham & Company LLCMay 12, 2024 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 4.8% May 11, 2024 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) to Post Q2 2024 Earnings of ($0.23) Per Share, Leerink Partnrs ForecastsMay 10, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 4.8%MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.8%May 10, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Buy Rating Justified by Strong Clinical Execution and Financial PositionMay 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for MoonLake Immunotherapeutics Decreased by Leerink Partnrs (NASDAQ:MLTX)MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Investment analysts at Leerink Partnrs reduced their Q2 2024 EPS estimates for shares of MoonLake Immunotherapeutics in a note issued to investors on Tuesday, May 7th. Leerink Partnrs analyst T. Smith now expects that the company will postMay 10, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)May 9, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by TimesSquare Capital Management LLCTimesSquare Capital Management LLC boosted its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 18.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 488,805 shares of the company's stock after acquiring an additMay 8, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a research report on Wednesday.May 8, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Earns Buy Rating: Advancing Clinical Programs and Strong Financial PositionMay 8, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics’ Strong Buy Rating: Promising Clinical Developments and Significant Market PotentialMay 8, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Announces Earnings Results, Misses Expectations By $0.03 EPSMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03).May 8, 2024 | finance.yahoo.comMoonLake Immunotherapeutics Reports Q1 2024 Financial OutcomesMay 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Curis (CRIS)May 7, 2024 | finance.yahoo.comMoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business UpdateApril 26, 2024 | markets.businessinsider.comStrong Buy Rating for MoonLake Immunotherapeutics Based on Promising Sonelokimab Clinical Trials and Market PotentialApril 23, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics: A Promising Outlook with Sonelokimab’s Potential in the HS MarketApril 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical Results for SonelokimabApril 19, 2024 | marketbeat.comFederated Hermes Inc. Trims Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)Federated Hermes Inc. lowered its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 2.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,060,526 shares of the company's stock after selling 23,724 shares during the period. FedApril 11, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Buy Rating: Strategic Partnerships and Market Potential Fuel OptimismApril 11, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of MoonLake Immunotherapeutics in a research note on Thursday.April 10, 2024 | businesswire.comMoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint ConditionsApril 10, 2024 | globenewswire.comMoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditionsApril 2, 2024 | msn.comGoldman starts MoonLake at neutral, cites lead drug potentialApril 2, 2024 | marketbeat.comThe Goldman Sachs Group Initiates Coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX)The Goldman Sachs Group assumed coverage on MoonLake Immunotherapeutics in a report on Tuesday. They issued a "neutral" rating and a $62.00 price objective on the stock.March 25, 2024 | finance.yahoo.comMLTX Aug 2024 80.000 callMarch 20, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.1%MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 4.1%March 18, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven ratings firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy ratingMarch 16, 2024 | marketbeat.comWalleye Capital LLC Purchases New Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX)Walleye Capital LLC purchased a new stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 67,926 shares of the company's stock, valued at approximaMarch 15, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 4.8%MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading 4.8% HigherMarch 12, 2024 | finance.yahoo.comMLTX May 2024 60.000 callMarch 12, 2024 | finance.yahoo.comMLTX Apr 2024 40.000 putMarch 11, 2024 | marketwatch.comMoonLake Immunotherapeutics Shares Rise Premarket After Pipeline UpdateMarch 11, 2024 | msn.comWhy Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?March 11, 2024 | marketbeat.comPolar Capital Holdings Plc Sells 676,377 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)Polar Capital Holdings Plc cut its holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 41.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 939,012 shares of the company's stock after sellingMarch 11, 2024 | realmoney.thestreet.comMoonLake price target raised to $100 from $75 at H.C. WainwrightMarch 10, 2024 | globenewswire.comMoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D DayMarch 7, 2024 | marketbeat.comQ1 2024 Earnings Estimate for MoonLake Immunotherapeutics (NASDAQ:MLTX) Issued By HC WainwrightMoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Research analysts at HC Wainwright raised their Q1 2024 earnings per share (EPS) estimates for shares of MoonLake Immunotherapeutics in a report issued on Monday, March 4th. HC Wainwright analyst R. Selvaraju now expects that the company wMarch 6, 2024 | marketbeat.comHC Wainwright Weighs in on MoonLake Immunotherapeutics' Q1 2025 Earnings (NASDAQ:MLTX)MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for shares of MoonLake Immunotherapeutics in a research note issued on Monday, March 4th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.75) per share forMarch 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical and Regulatory AdvancesMarch 4, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Has $111.30 Million Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)Adage Capital Partners GP L.L.C. grew its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 42.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,952,703 shares of the company's stock after pMarch 4, 2024 | marketbeat.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $75.00 price target on shares of MoonLake Immunotherapeutics in a research report on Monday.March 4, 2024 | globenewswire.comMoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address What President Biden's new law means for investors (Ad)What's Got Musk, Bezos, and Gates So Excited? Billionaires are plowing millions of dollars into a new technology that early estimates say could generate more wealth than A.I. – and determine the future of companies like Microsoft. The problem? Most investors have no idea it's happening, or how to profit on it. This expert just went public with all the details, including which stocks to jump on immediately. MLTX Media Mentions By Week MLTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MLTX News Sentiment▼0.340.42▲Average Medical News Sentiment MLTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MLTX Articles This Week▼93▲MLTX Articles Average Week Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BHC News Today MRUS News Today MRVI News Today JANX News Today RYTM News Today DYN News Today ACAD News Today FOLD News Today RNA News Today MOR News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MLTX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profits4 Cryptos BETTER than BitcoinTrue Market InsidersNext President (Not Trump. Not Biden.)The Freeport SocietyThe #1 Crypto for AIWeiss Ratings**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
